秋水仙碱治疗冠心病的研究进展

王丽; 宋立君; 卢成志

doi:10.13201/j.issn.1001-1439.2021.07.003

秋水仙碱治疗冠心病的研究进展

- 1. 天津市第一中心医院心内科(天津, 300192);
- 2. 天津市第一中心医院消化科
基金项目:
天津市科技人才培育项目(No:RC20181)

详细信息

通讯作者: 卢成志,E-mail:lucz8@126.com

中图分类号: R541.4

收稿日期: 2020-12-10

Advances in colchicine treatment of coronary heart disease

- 1. Department of Cardiology,Tianjin First Central Hospital, Tianjin, 300192, China;
- 2. Department of Digestive,Tianjin First Central Hospital

More Information

Corresponding author: LU Chengzhi, E-mail: lucz8@126.com

Received Date: 10 December 2020

摘要

摘要: 目前多数学者认为冠心病是慢性炎症性疾病,但该疾病的抗炎治疗药物发展步履维艰。近年研究显示长期使用秋水仙碱可降低急慢性冠状动脉综合征的发生率,具有良好的安全性。本文就秋水仙碱对冠心病病理生理的影响,以及近年来重要的临床研究进行讨论。
- 冠心病 /
- 急性冠状动脉综合征 /
- 心肌梗死 /
- 秋水仙碱
Abstract: More and more evidences indicate that coronary artery disease is a chronic inflammatory disease. But the development of anti-inflammatory drugs for the disease has been struggling. Long-term use of colchicine has been associated with a reduced rate of chronic and acute coronary syndromes. This review will focus on the influence of colchicine on the pathophysiology of coronary artery disease, and discuss the recent clinical studies.
- coronary artery disease /
- acute coronary syndrome /
- myocardial infarction /
- colchicine

HTML全文

参考文献(35)

[1]	帕孜丽亚·阿地力穆叶赛·尼加提,等.动脉粥样硬化与炎症[J].临床心血管病杂志,2020,36(4):303-306.
[2]	Tuňón J,Badimón L,Bochaton-Piallat ML,et al.Identifying the anti-inflammatory response to lipid lowering therapy:a position paper from the working group on atherosclerosis and vascular biology of the European Society of Cardiology[J].Cardiovasc Res,2019,115(1):10-19.
[3]	Ridker PM.From CANTOS to CIRT to COLCOT to Clinic:Will All atherosclerosis patients soon be treated with combination lipid-lowering and inflammation-inhibiting agents?[J].Circulation,2020,141(10):787-789.
[4]	Ridker PM,Everett BM,Pradhan A,et al.Low-dose methotrexate for the prevention of atherosclerotic events[J].N Engl J Med,2019,380(8):752-762.
[5]	Leung YY,Yao Hui LL,Kraus VB.Colchicine--Update on mechanisms of action and therapeutic uses[J].Semin Arthritis Rheum,2015,45(3):341-350.
[6]	Nidorf SM,Fiolet A,Eikelboom JW,et al.The effect of low-dose colchicine in patients with stable coronary artery disease:The LoDoCo2 trial rationale,design,and baseline characteristics[J].Am Heart J,2019,218:46-56.
[7]	Nidorf SM,Thompson PL.Why Colchicine should be considered for secondary prevention of atherosclerosis:an overview[J].Clin Ther,2019,41(1):41-48.
[8]	Yang M,Lv H,Liu Q,et al.Colchicine alleviates cholesterol crystal-induced endothelial cell pyroptosis through activating AMPK/SIRT1 pathway[J].Oxid Med Cell Longev,2020,2020:9173530.
[9]	Reddel CJ,Pennings GJ,Curnow JL,et al.Procoagulant effects of low-level platelet activation and its inhibition by colchicine[J].Thromb Haemost,2018,118(4):723-733.
[10]	Cimmino G,Tarallo R,Conte S,et al.Colchicine reduces platelet aggregation by modulating cytoskeleton rearrangement via inhibition of cofilin and LIM domain kinase 1[J].Vascul Pharmacol,2018,111:62-70.
[11]	Shah B,Allen N,Harchandani B,et al.Effect of colchicine on platelet-platelet and platelet-leukocyte interactions:a pilot study in healthy subjects[J].Inflammation,2016,39(1):182-189.
[12]	Cimmino G,Conte S,Morello A,et al.Colchicine inhibits the prothrombotic effects of oxLDL in human endothelial cells[J].Vascul Pharmacol,2021,137:106822.
[13]	Opstal T,Hoogeveen RM,Fiolet A,et al.Colchicine attenuates inflammation beyond the inflammasome in chronic coronary artery disease:a LoDoCo2 proteomic substudy[J].Circulation,2020,142(20):1996-1998.
[14]	Cecconi A,Vilchez-Tschischke JP,Mateo J,et al.Effects of colchicine on atherosclerotic plaque stabilization:a multimodality imaging study in an animal model[J].J Cardiovasc Transl Res,2021,14(1):150-160.
[15]	Nidorf SM,Eikelboom JW,Budgeon CA,et al.Low-dose colchicine for secondary prevention of cardiovascular disease[J].J Am Coll Cardiol,2013,61(4):404-410.
[16]	Samuel M,Tardif JC,Bouabdallaoui N,et al.Colchicine for secondary prevention of cardiovascular disease:a systematic review and meta-analysis of randomized controlled trials[J].Can J Cardiol,2021,37(5):776-785.
[17]	Fiolet A,Nidorf SM,Cornel JH,et al.Colchicine for secondary prevention in coronary disease[J].Eur Heart J,2021,42(11):1060-1061.
[18]	Nidorf SM,Fiolet A,Mosterd A,et al.Colchicine in patients with chronic coronary disease[J].N Engl J Med,2020,383(19):1838-1847.
[19]	Vaidya K,Arnott C,Martínez GJ,et al.Colchicine therapy and plaque stabilization in patients with acute coronary syndrome:a CT coronary angiography study[J].JACC Cardiovasc Imaging,2018,11(2 Pt 2):305-316.
[20]	Robertson S,Martínez GJ,Payet CA,et al.Colchicine therapy in acute coronary syndrome patients acts on caspase-1 to suppress NLRP3 inflammasome monocyte activation[J].Clin Sci(Lond),2016,130(14):1237-1246.
[21]	Tong DC,Quinn S,Nasis A,et al.Colchicine in patients with acute coronary syndrome:the Australian COPS Randomized Clinical Trial[J].Circulation,2020,142(20):1890-1900.
[22]	Deftereos S,Giannopoulos G,Angelidis C,et al.Anti-inflammatory treatment with colchicine in acute myocardial infarction:a pilot study[J].Circulation,2015,132(15):1395-403.
[23]	Hennessy T,Soh L,Bowman M,et al.The low dose colchicine after myocardial infarction(LoDoCo-MI)study:A pilot randomized placebo controlled trial of colchicine following acute myocardial infarction[J].Am Heart J,2019,215:62-69.
[24]	Aimo A,Pascual-Figal DA,Barison A,et al.Colchicine for the treatment of coronary artery disease[J].Trends Cardiovasc Med,2020,120:11.
[25]	Tardif JC,Kouz S,Waters DD,et al.Efficacy and safety of low-dose colchicine after myocardial infarction[J].N Engl J Med,2019,381(26):2497-2505.
[26]	Bouabdallaoui N,Tardif JC,Waters DD,et al.Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial(COLCOT)[J].Eur Heart J,2020,41(42):4092-4099.
[27]	Deftereos S,Giannopoulos G,Raisakis K,et al.Colchicine treatment for the prevention of bare-metal stent restenosis in diabetic patients[J].J Am Coll Cardiol,2013,61(16):1679-1685.
[28]	Shah B,Pillinger M,Zhong H,et al.Effects of acute colchicine administration prior to percutaneous coronary intervention:COLCHICINE-PCI randomized trial[J].Circ Cardiovasc Interv,2020,13(4):e008717.
[29]	Ashish K,Bandyopadhyay D,Mondal S,et al.Colchicine in coronary artery disease:Role of anti-inflammatory medications redefined[J].Int J Cardiol,2018,254:51.
[30]	Stewart S,Yang K,Atkins K,et al.Adverse events during oral colchicine use:a systematic review and meta-analysis of randomised controlled trials[J].Arthritis Res Ther,2020,22(1):28.
[31]	Fernández-Ruiz I.Low-dose colchicine shows promise in chronic coronary disease[J].Nat Rev Cardiol,2020,17(11):680-681.
[32]	Schenone AL,Menon V.Colchicine in pericardial disease:from the underlying biology and clinical benefits to the drug-drug interactions in cardiovascular medicine[J].Curr Cardiol Rep,2018,20(8):62.
[33]	Nomani H,Saei S,Johnston TP,et al.The efficacy of anti-inflammatory agents in the prevention of atrial fibrillation recurrences[J].Curr Med Chem,2021,28(1):137-151.
[34]	Caso V,Mas JL.Optimization of stroke prevention:colchicine may be an option[J].Eur J Neurol,2020,27(7):1099.
[35]	Demidowich AP,Levine JA,Apps R,et al.Colchicine's effects on metabolic and inflammatory molecules in adults with obesity and metabolic syndrome:results from a pilot randomized controlled trial[J].Int J Obes(Lond),2020,44(8):1793-1799.